A multicenter, randomized, open label study to evaluate the lipid lowering efficacy and safety of Vytorin [ezetimibe/simvastatin] 10/20 vs. atorvastatin 10mg in hypercholesterolemia patients with metabolic syndrome in Korea
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Organon
- 17 Dec 2009 Actual patient number changed from 260 to 256 as reported by ClinicalTrials.gov.
- 26 Sep 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 25 Sep 2008 Actual patient number (260) added as reported by ClinicalTrials.gov.